The O'Reilly Update, April 11, 2026

In a rare moment of self-reflection, Bill O'Reilly claims credit for predicting President Trump’s extension of Iran negotiations, citing inside access to the White House. He argues Trump’s reluctance to bomb Iran stems from a desire to avoid civilian casualties, though he warns the deal could collapse, triggering a full-scale military response. O’Reilly frames the Iran crisis as a high-stakes diplomatic gamble, with the Strait of Hormuz at the center of a geopolitical flashpoint where Iran’s attempt to charge tolls has drawn international condemnation. Meanwhile, the First Lady publicly denies years-old allegations linking her to Jeffrey Epstein, calling the claims 'completely false' and urging caution against misinformation. On a lighter note, O’Reilly reveals a surprising shift in public health: GLP-1 weight-loss drugs—originally developed for diabetes—are now driving a historic decline in U.S. obesity rates, despite serious side effects and a $60 billion industry that’s growing rapidly. Yet, even as celebrities tout the drugs, countries like the UK and Belgium are restricting access due to safety concerns.